Nuvation Bio Stock Performance
| NUVB Stock | USD 2.30 0.06 2.68% |
On a scale of 0 to 100, Nuvation Bio holds a performance score of 5. The company secures a Beta (Market Risk) of 1.81, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nuvation Bio will likely underperform. Please check Nuvation Bio's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Nuvation Bio's current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nuvation Bio are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat conflicting basic indicators, Nuvation Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.45 | Five Day Return 4.07 | Year To Date Return (11.20) | Ten Year Return (77.00) | All Time Return (77.00) |
1 | Disposition of 20000 shares by Liu Dongfang of Nuvation Bio at 2.5012 subject to Rule 16b-3 | 05/02/2025 |
2 | Q1 2025 Nuvation Bio Inc Earnings Call and Business Update Transcript | 05/09/2025 |
3 | Acquisition by Kathryn Falberg of 292983 shares of Nuvation Bio at 2.03 subject to Rule 16b-3 | 05/30/2025 |
4 | FDA Approval Boosts Nuvation Bios Ibtrozi for Lung Cancer Treatment NUVB Stock News | 06/11/2025 |
5 | Acquisition by David Hung of 500000 shares of Nuvation Bio at 1.787 subject to Rule 16b-3 | 06/16/2025 |
6 | Nuvation Bio RBC Capital Maintains Rating, Lowers Price Target NUVB Stock News | 06/17/2025 |
7 | Acquisition by Stacy Markel of 10000 shares of Nuvation Bio at 1.71 subject to Rule 16b-3 | 06/18/2025 |
8 | Insider Buying Boosts Nuvation Bio Shares Amidst FDA Approval Impact | 06/20/2025 |
9 | Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS... | 06/24/2025 |
10 | Nuvation Bio Maintains Market Outperform Rating by JMP Securities NUVB Stock News | 06/25/2025 |
11 | Acquisition by Cui Xiangmin of 175346 shares of Nuvation Bio at 11.5 subject to Rule 16b-3 | 06/30/2025 |
12 | All You Need to Know About Nuvation Bio Rating Upgrade to Buy | 07/09/2025 |
13 | Is Nuvation Bio Inc. a good long term investment - Consistently high yield - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 42.6 M | |
| Total Cashflows From Investing Activities | 122.7 M |
Nuvation Bio Relative Risk vs. Return Landscape
If you would invest 198.00 in Nuvation Bio on April 21, 2025 and sell it today you would earn a total of 32.00 from holding Nuvation Bio or generate 16.16% return on investment over 90 days. Nuvation Bio is currently generating 0.3908% in daily expected returns and assumes 5.5169% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Nuvation, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nuvation Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nuvation Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nuvation Bio, and traders can use it to determine the average amount a Nuvation Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0708
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NUVB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.52 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Nuvation Bio is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nuvation Bio by adding it to a well-diversified portfolio.
Nuvation Bio Fundamentals Growth
Nuvation Stock prices reflect investors' perceptions of the future prospects and financial health of Nuvation Bio, and Nuvation Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nuvation Stock performance.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (19.13) % | ||||
| Current Valuation | 332.34 M | ||||
| Shares Outstanding | 339.26 M | ||||
| Price To Book | 1.87 X | ||||
| Price To Sales | 71.43 X | ||||
| Revenue | 7.87 M | ||||
| Gross Profit | 1.78 M | ||||
| EBITDA | (566.91 M) | ||||
| Net Income | (567.94 M) | ||||
| Cash And Equivalents | 703.8 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 8.91 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.58 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (130.41 M) | ||||
| Earnings Per Share | (2.20) X | ||||
| Market Capitalization | 782.6 M | ||||
| Total Asset | 540.63 M | ||||
| Retained Earnings | (910.74 M) | ||||
| Working Capital | 468.01 M | ||||
About Nuvation Bio Performance
By analyzing Nuvation Bio's fundamental ratios, stakeholders can gain valuable insights into Nuvation Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nuvation Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nuvation Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.11) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.05) | (1.10) | |
| Return On Equity | (1.22) | (1.16) |
Things to note about Nuvation Bio performance evaluation
Checking the ongoing alerts about Nuvation Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nuvation Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nuvation Bio had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 7.87 M. Net Loss for the year was (567.94 M) with profit before overhead, payroll, taxes, and interest of 1.78 M. | |
| Nuvation Bio currently holds about 703.8 M in cash with (130.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nuvation Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: GAMMA Investing LLC Boosts Stock Position in Cullinan Therapeutics, Inc. - Defense World |
- Analyzing Nuvation Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nuvation Bio's stock is overvalued or undervalued compared to its peers.
- Examining Nuvation Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nuvation Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nuvation Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nuvation Bio's stock. These opinions can provide insight into Nuvation Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nuvation Stock analysis
When running Nuvation Bio's price analysis, check to measure Nuvation Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvation Bio is operating at the current time. Most of Nuvation Bio's value examination focuses on studying past and present price action to predict the probability of Nuvation Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvation Bio's price. Additionally, you may evaluate how the addition of Nuvation Bio to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |